Aethlon Medical

Aethlon Medical EBITDA per Share

The EBITDA per Share of Aethlon Medical (AEMD) as of Nov 18, 2026 is -18.96 USD. In the previous year, EBITDA per Share was -11.35 USD — a change of 67.06% (lower).

EBITDA per Share

-18.96USD

YoY

67.06%

Last updated:

EBITDA per Share of Aethlon Medical is 2026 -18.96 USD. EBITDA per Share of Aethlon Medical was 2025 -11.35 USD. It decreases by 67.06% lower compared to the previous year.

The Aethlon Medical EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2019
-207.60 USD
Jan 1, 2020
-418.93 USD
Jan 1, 2021
-410.93 USD
Jan 1, 2022
-363.10 USD
Jan 1, 2023
-377.73 USD
Jan 1, 2024
-72.42 USD
Jan 1, 2025
-11.35 USD
Jan 1, 2026
-18.96 USD
The Aethlon Medical EBITDA per Share history
YEAREBITDA per ShareYoY
-18.96USD+67.06%
-11.35USD-84.33%
-72.42USD-80.83%
-377.73USD+4.03%
-363.10USD-11.64%
-410.93USD-1.91%
-418.93USD+101.80%
-207.60USD-53.34%
-444.89USD+533.41%
-70.24USD-91.51%
-827.36USD+5.67%
-782.94USD+2.48%
-764.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Aethlon Medical Stock analysis

What does Aethlon Medical do? Aethlon Medical, Inc. generates revenue through its therapeutic and diagnostic segments. The Aethlon segment focuses on the Aethlon Hemopurifier, a device targeting circulating viruses and tumor-secreted exosomes for oncology treatment. The ESI segment, representing diagnostic activities, develops exosome-based product candidates via its subsidiary Exosome Sciences, Inc. (Exosome) for diagnosing neurological disorders and cancer. Customers include healthcare providers seeking innovative treatments for viral infections and cancer progression. The Aethlon Hemopurifier eliminates circulating viruses and exosomes by shedding glycoproteins, addressing both infectious diseases and oncology needs. Exosome Sciences, Inc. (Exosome) develops diagnostic tools using exosomes to monitor neurological conditions and cancer, targeting healthcare institutions and research partners. Revenue streams come from therapeutic device sales and diagnostic product development under the Aethlon and ESI segments. Aethlon Medical, Inc. operates through two business segments: Aethlon for therapeutic products like the Hemopurifier and ESI for diagnostic solutions through Exosome Sciences, Inc. (Exosome). The company's lead product, the Aethlon Hemopurifier, is sold to healthcare providers for treating viral pathogens and cancer metastasis, while Exosome develops exosome-based diagnostics for neurological disorders and cancer monitoring. The firm's revenue is derived from these two segment activities without mentioning external partners or additional financial details. Aethlon Medical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Aethlon Medical stock

EBITDA per Share of Aethlon Medical is -18.96 USD in 2026.

EBITDA per Share of Aethlon Medical changed from -11.35 USD to -18.96 USD, representing a 67.06% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Aethlon Medical since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Aethlon Medical

All Key Metrics — Aethlon Medical